Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-01-10

AUTHORS

Hiroaki Ueno, Hiroko Nakazato, Emi Ebihara, Kenji Noma, Takahisa Kawano, Kazuhiro Nagamine, Hideyuki Sakoda, Masamitsu Nakazato

ABSTRACT

IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12 weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195). More... »

PAGES

403-411

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8

DOI

http://dx.doi.org/10.1007/s13300-018-0366-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100290978

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29322485


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "Hiroaki", 
        "id": "sg:person.011104371372.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104371372.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakazato", 
        "givenName": "Hiroko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ebihara", 
        "givenName": "Emi", 
        "id": "sg:person.016011371614.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016011371614.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Noma Naika Clinic, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Noma Naika Clinic, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noma", 
        "givenName": "Kenji", 
        "id": "sg:person.0736512042.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736512042.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kawano Naika Clinic, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Kawano Naika Clinic, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawano", 
        "givenName": "Takahisa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagamine", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.0617541045.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617541045.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakoda", 
        "givenName": "Hideyuki", 
        "id": "sg:person.0774327434.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774327434.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410849.0", 
          "name": [
            "Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakazato", 
        "givenName": "Masamitsu", 
        "id": "sg:person.0725136110.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725136110.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-014-0089-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005793567", 
          "https://doi.org/10.1007/s13300-014-0089-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-014-3283-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031625562", 
          "https://doi.org/10.1007/s00125-014-3283-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40268-016-0137-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007120806", 
          "https://doi.org/10.1007/s40268-016-0137-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-016-0211-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017299918", 
          "https://doi.org/10.1007/s13300-016-0211-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0277-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090744326", 
          "https://doi.org/10.1007/s13300-017-0277-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-01-10", 
    "datePublishedReg": "2018-01-10", 
    "description": "IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50\u00a0mg/day) for 12\u00a0weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12\u00a0weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-018-0366-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "glucagon-like peptide-1", 
      "glucose-dependent insulinotropic polypeptide", 
      "active glucose-dependent insulinotropic polypeptide", 
      "type 2 diabetes mellitus", 
      "sodium-glucose cotransporter 2", 
      "effect of ipragliflozin", 
      "des-acyl ghrelin", 
      "ipragliflozin treatment", 
      "diabetes mellitus", 
      "active glucagon-like peptide-1", 
      "serum uric acid levels", 
      "gastrointestinal peptide responses", 
      "glucose-lowering mechanisms", 
      "inappropriate glucagon secretion", 
      "postprandial insulin requirement", 
      "systolic blood pressure", 
      "active GLP-1", 
      "meal tolerance test", 
      "body fat mass", 
      "uric acid levels", 
      "postprandial glucose metabolism", 
      "novel antidiabetic drugs", 
      "Medical Information Network", 
      "postprandial glucagon", 
      "insulin requirements", 
      "ResultsBody weight", 
      "blood pressure", 
      "glycemic control", 
      "postprandial glucose", 
      "glucagon secretion", 
      "insulin levels", 
      "gut peptides", 
      "tolerance test", 
      "insulinotropic polypeptide", 
      "Japanese patients", 
      "fat mass", 
      "cotransporter 2", 
      "postprandial profiles", 
      "antidiabetic drugs", 
      "ipragliflozin", 
      "peptide-1", 
      "short-term studies", 
      "glucose metabolism", 
      "body weight", 
      "peptide response", 
      "ghrelin", 
      "type 2", 
      "pilot study", 
      "small sample size", 
      "acid levels", 
      "glucagon", 
      "mellitus", 
      "obesity", 
      "treatment", 
      "patients", 
      "insulin", 
      "weeks", 
      "glucose", 
      "sample size", 
      "HbA1c", 
      "secretion", 
      "drugs", 
      "study", 
      "levels", 
      "weight", 
      "metabolism", 
      "effect", 
      "aim", 
      "peptides", 
      "response", 
      "control", 
      "benefits", 
      "test", 
      "profile", 
      "pressure", 
      "mechanism", 
      "polypeptide", 
      "mass", 
      "increment", 
      "size", 
      "information networks", 
      "requirements", 
      "network"
    ], 
    "name": "Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study", 
    "pagination": "403-411", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100290978"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-018-0366-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29322485"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-018-0366-8", 
      "https://app.dimensions.ai/details/publication/pub.1100290978"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_787.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-018-0366-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-018-0366-8'


 

This table displays all metadata directly associated to this object as RDF triples.

216 TRIPLES      21 PREDICATES      113 URIs      100 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-018-0366-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N6a34effa5dac41169a9d8a00fc2a5338
4 schema:citation sg:pub.10.1007/s00125-014-3283-z
5 sg:pub.10.1007/s13300-014-0089-4
6 sg:pub.10.1007/s13300-016-0211-x
7 sg:pub.10.1007/s13300-017-0277-0
8 sg:pub.10.1007/s40268-016-0137-9
9 schema:datePublished 2018-01-10
10 schema:datePublishedReg 2018-01-10
11 schema:description IntroductionIpragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.MethodsNine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12 weeks after ipragliflozin treatment.ResultsBody weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.ConclusionIpragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.Trial RegistrationUniversity Hospital Medical Information Network (UMIN No. 000017195).
12 schema:genre article
13 schema:isAccessibleForFree true
14 schema:isPartOf N4efcaf02f6ae455981049931446764b1
15 N68849f1b3aa445b1988817ac23d70395
16 sg:journal.1044057
17 schema:keywords HbA1c
18 Japanese patients
19 Medical Information Network
20 ResultsBody weight
21 acid levels
22 active GLP-1
23 active glucagon-like peptide-1
24 active glucose-dependent insulinotropic polypeptide
25 aim
26 antidiabetic drugs
27 benefits
28 blood pressure
29 body fat mass
30 body weight
31 control
32 cotransporter 2
33 des-acyl ghrelin
34 diabetes mellitus
35 drugs
36 effect
37 effect of ipragliflozin
38 fat mass
39 gastrointestinal peptide responses
40 ghrelin
41 glucagon
42 glucagon secretion
43 glucagon-like peptide-1
44 glucose
45 glucose metabolism
46 glucose-dependent insulinotropic polypeptide
47 glucose-lowering mechanisms
48 glycemic control
49 gut peptides
50 inappropriate glucagon secretion
51 increment
52 information networks
53 insulin
54 insulin levels
55 insulin requirements
56 insulinotropic polypeptide
57 ipragliflozin
58 ipragliflozin treatment
59 levels
60 mass
61 meal tolerance test
62 mechanism
63 mellitus
64 metabolism
65 network
66 novel antidiabetic drugs
67 obesity
68 patients
69 peptide response
70 peptide-1
71 peptides
72 pilot study
73 polypeptide
74 postprandial glucagon
75 postprandial glucose
76 postprandial glucose metabolism
77 postprandial insulin requirement
78 postprandial profiles
79 pressure
80 profile
81 requirements
82 response
83 sample size
84 secretion
85 serum uric acid levels
86 short-term studies
87 size
88 small sample size
89 sodium-glucose cotransporter 2
90 study
91 systolic blood pressure
92 test
93 tolerance test
94 treatment
95 type 2
96 type 2 diabetes mellitus
97 uric acid levels
98 weeks
99 weight
100 schema:name Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
101 schema:pagination 403-411
102 schema:productId N9347b37106c54a208eb5b1d0c9e6288d
103 Nc8bcc3ac7c3a424a98c44330b9cd2082
104 Nd1747b33683a4d5da2f8e0383404bade
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100290978
106 https://doi.org/10.1007/s13300-018-0366-8
107 schema:sdDatePublished 2022-10-01T06:44
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N09a268a114e34ace97946ea095c675a2
110 schema:url https://doi.org/10.1007/s13300-018-0366-8
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N09a268a114e34ace97946ea095c675a2 schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 N1c11cbbe34914822b71427796bdbd1e0 rdf:first sg:person.0736512042.97
117 rdf:rest N86a01e6b7e2d4dfba8c8038b77a44fd9
118 N228cc0957c2443af831182adc2b10edd rdf:first sg:person.016011371614.52
119 rdf:rest N1c11cbbe34914822b71427796bdbd1e0
120 N4efcaf02f6ae455981049931446764b1 schema:volumeNumber 9
121 rdf:type schema:PublicationVolume
122 N68849f1b3aa445b1988817ac23d70395 schema:issueNumber 1
123 rdf:type schema:PublicationIssue
124 N6a34effa5dac41169a9d8a00fc2a5338 rdf:first sg:person.011104371372.49
125 rdf:rest N8b5276846e2e4e99b28ca0b88bb71845
126 N6f2978eacf2a44818f408730037d119a rdf:first sg:person.0774327434.28
127 rdf:rest Nb9aeb50924614fd59da7694020fcc19b
128 N86a01e6b7e2d4dfba8c8038b77a44fd9 rdf:first Nb32e2971a0e647c69b1feebf23d8092c
129 rdf:rest Nfd93bfe40056455c9d8d030c39ca0c56
130 N8b5276846e2e4e99b28ca0b88bb71845 rdf:first N8b8c5630370e4c46b48e5595565d6b2c
131 rdf:rest N228cc0957c2443af831182adc2b10edd
132 N8b8c5630370e4c46b48e5595565d6b2c schema:affiliation grid-institutes:grid.410849.0
133 schema:familyName Nakazato
134 schema:givenName Hiroko
135 rdf:type schema:Person
136 N9347b37106c54a208eb5b1d0c9e6288d schema:name pubmed_id
137 schema:value 29322485
138 rdf:type schema:PropertyValue
139 Nb32e2971a0e647c69b1feebf23d8092c schema:affiliation grid-institutes:None
140 schema:familyName Kawano
141 schema:givenName Takahisa
142 rdf:type schema:Person
143 Nb9aeb50924614fd59da7694020fcc19b rdf:first sg:person.0725136110.34
144 rdf:rest rdf:nil
145 Nc8bcc3ac7c3a424a98c44330b9cd2082 schema:name dimensions_id
146 schema:value pub.1100290978
147 rdf:type schema:PropertyValue
148 Nd1747b33683a4d5da2f8e0383404bade schema:name doi
149 schema:value 10.1007/s13300-018-0366-8
150 rdf:type schema:PropertyValue
151 Nfd93bfe40056455c9d8d030c39ca0c56 rdf:first sg:person.0617541045.47
152 rdf:rest N6f2978eacf2a44818f408730037d119a
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:journal.1044057 schema:issn 1869-6953
160 1869-6961
161 schema:name Diabetes Therapy
162 schema:publisher Springer Nature
163 rdf:type schema:Periodical
164 sg:person.011104371372.49 schema:affiliation grid-institutes:grid.410849.0
165 schema:familyName Ueno
166 schema:givenName Hiroaki
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011104371372.49
168 rdf:type schema:Person
169 sg:person.016011371614.52 schema:affiliation grid-institutes:grid.410849.0
170 schema:familyName Ebihara
171 schema:givenName Emi
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016011371614.52
173 rdf:type schema:Person
174 sg:person.0617541045.47 schema:affiliation grid-institutes:grid.410849.0
175 schema:familyName Nagamine
176 schema:givenName Kazuhiro
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617541045.47
178 rdf:type schema:Person
179 sg:person.0725136110.34 schema:affiliation grid-institutes:grid.410849.0
180 schema:familyName Nakazato
181 schema:givenName Masamitsu
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725136110.34
183 rdf:type schema:Person
184 sg:person.0736512042.97 schema:affiliation grid-institutes:None
185 schema:familyName Noma
186 schema:givenName Kenji
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736512042.97
188 rdf:type schema:Person
189 sg:person.0774327434.28 schema:affiliation grid-institutes:grid.410849.0
190 schema:familyName Sakoda
191 schema:givenName Hideyuki
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774327434.28
193 rdf:type schema:Person
194 sg:pub.10.1007/s00125-014-3283-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1031625562
195 https://doi.org/10.1007/s00125-014-3283-z
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/s13300-014-0089-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005793567
198 https://doi.org/10.1007/s13300-014-0089-4
199 rdf:type schema:CreativeWork
200 sg:pub.10.1007/s13300-016-0211-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017299918
201 https://doi.org/10.1007/s13300-016-0211-x
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/s13300-017-0277-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090744326
204 https://doi.org/10.1007/s13300-017-0277-0
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/s40268-016-0137-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007120806
207 https://doi.org/10.1007/s40268-016-0137-9
208 rdf:type schema:CreativeWork
209 grid-institutes:None schema:alternateName Kawano Naika Clinic, Miyazaki, Japan
210 Noma Naika Clinic, Miyazaki, Japan
211 schema:name Kawano Naika Clinic, Miyazaki, Japan
212 Noma Naika Clinic, Miyazaki, Japan
213 rdf:type schema:Organization
214 grid-institutes:grid.410849.0 schema:alternateName Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
215 schema:name Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
216 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...